Deferasirox

地拉罗司

Report date: 2026/03/11 20:02:12
NME

Base Information

Drug NameDeferasirox
Drug Alias Name去铁斯若Deferasiroxum地拉罗斯恩瑞格Exjade +[12] 
ClassificationSmall molecules > Polymers and chelators
Mechanisms of ActionIron chelating agents
TargetsNot applicable
Therapy Area/IndicationsAngioimmunoblastic T-cell LymphomaHemosiderosisIron Overload +[53] 
Global Approved IndicationsIron Overloadbeta-Thalassemia
Approved Indications in ChinaIron Overload
Original Approved Country/TerritoryUnited States
Original Approved Date2005/11/02
Country/TerritoryBelgiumBulgariaCanada +[51] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma Schweiz AgNovartis Pharma AgNovartis Pharmaceuticals Corp +[5] 
Inactive CompaniesUniversity of Texas Southwestern Medical CenterWake Forest University Health SciencesMasonic Cancer Center, University Of Minnesota +[7] 
Active IndicationsIron OverloadMyelodysplastic Syndromesbeta-Thalassemia +[6] 
Inactive IndicationsAngioimmunoblastic T-cell LymphomaHemosiderosisHemochromatosis +[47] 

Other Information

ATC CodeV03AC03
Related LinksWikipediaDrugBankKEGG